Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sezary Syndrome 3Lymphoma, T-Cell, Peripheral 3Leukemia-Lymphoma, Adult T-Cell 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Rituximab 134Cyclophosphamide 100Vincristine 53fludarabine phosphate 50Prednisone 50Doxorubicin 49Etoposide 47Peripheral Blood Stem Cell Transplantation 38Mycophenolic Acid 37Whole-Body Irradiation 35Tacrolimus 29Busulfan 27Lenalidomide 26Filgrastim 26Cyclosporine 26Melphalan 24Methotrexate 21Antilymphocyte Serum 21Gemcitabine 18ibritumomab tiuxetan 17Granulocyte Colony-Stimulating Factor 17Cytarabine 17Carmustine 16Radiotherapy 15fludarabine 14Carboplatin 14Bendamustine Hydrochloride 14pembrolizumab 13ibrutinib 12Sirolimus 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large B-Cell, Diffuse × mogamulizumab × Clear all
NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 10 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡